


# ABSTRACT OF THE DISCLOSURE

This invention provides compounds defined by Formula I

5



I

or a pharmaceutically acceptable salt thereof,

wherein R<sup>1</sup>, Q, Y<sup>1</sup>, Y<sup>3</sup>, Y<sup>5</sup>, Y<sup>6</sup>, Y<sup>8</sup>, and R<sup>2</sup> are as defined in the specification. The

invention also provides pharmaceutical compositions comprising a compound of

Formula I, or a pharmaceutically acceptable salt thereof, as defined in the

10

specification, together with a pharmaceutically acceptable carrier, diluent, or

excipient. The invention also provides methods of inhibiting an MMP-13 enzyme

in an animal, comprising administering to the animal a compound of Formula I, or

a pharmaceutically acceptable salt thereof. The invention also provides methods

of treating a disease mediated by an MMP-13 enzyme in a patient, comprising

15

administering to the patient a compound of Formula I, or a pharmaceutically

acceptable salt thereof, either alone or in a pharmaceutical composition. The

invention also provides methods of treating diseases such as heart disease,

multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or

rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart

20

failure, age-related macular degeneration, chronic obstructive pulmonary disease,

asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a

patient, comprising administering to the patient a compound of Formula I, or a

pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical

composition. The invention also provides combinations, comprising a compound

25

of Formula I, or a pharmaceutically acceptable salt thereof, together with another

pharmaceutically active component as described in the specification.

30